Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christy M Finke

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Blood Cancer Journal|January 24, 2018
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimentalMrinal M Patnaik, Rangit Vallapureddy, Terra L Lasho, et al.
American Journal of Hematology|June 8, 2019
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosisGiacomo Coltro, Terra L Lasho, Christy M Finke, et al.
European Journal of Haematology|December 18, 2007
Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlatesNaseema Gangat, Jacob Strand, Terra L Lasho, et al.
American Journal of Hematology|March 18, 2017
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemiaMrinal M Patnaik, Daniela Barraco, Terra L Lasho, et al.
American Journal of Hematology|December 6, 2018
20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patientsDomenico Penna, Terra L Lasho, Christy M Finke, et al.
Blood|October 11, 2014
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsAyalew Tefferi, Terra L Lasho, Alexander Tischer, et al.
Blood Cancer Journal|November 21, 2018
Genetic predictors of response to specific drugs in primary myelofibrosisDomenico Penna, Natasha Szuber, Terra L Lasho, et al.
Blood Cancer Journal|January 26, 2019
A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapyNaseema Gangat, Amy Phelps, Terra L Lasho, et al.
American Journal of Hematology|April 28, 2011
Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patientsMrinal M Patnaik, Terra L Lasho, Christy M Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasmsAnimesh Pardanani, Terra L Lasho, Christy M Finke, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Blood Cancer Journal|January 24, 2018
EZH2 mutations in chronic myelomonocytic leukemia cluster with ASXL1 mutations and their co-occurrence is prognostically detrimentalMrinal M Patnaik, Rangit Vallapureddy, Terra L Lasho, et al.
American Journal of Hematology|June 8, 2019
Germline SH2B3 pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosisGiacomo Coltro, Terra L Lasho, Christy M Finke, et al.
European Journal of Haematology|December 18, 2007
Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlatesNaseema Gangat, Jacob Strand, Terra L Lasho, et al.
American Journal of Hematology|March 18, 2017
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemiaMrinal M Patnaik, Daniela Barraco, Terra L Lasho, et al.
American Journal of Hematology|December 6, 2018
20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patientsDomenico Penna, Terra L Lasho, Christy M Finke, et al.
Blood|October 11, 2014
The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variantsAyalew Tefferi, Terra L Lasho, Alexander Tischer, et al.
Blood Cancer Journal|November 21, 2018
Genetic predictors of response to specific drugs in primary myelofibrosisDomenico Penna, Natasha Szuber, Terra L Lasho, et al.
Blood Cancer Journal|January 26, 2019
A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapyNaseema Gangat, Amy Phelps, Terra L Lasho, et al.
American Journal of Hematology|April 28, 2011
Isolated del(5q) in myeloid malignancies: clinicopathologic and molecular features in 143 consecutive patientsMrinal M Patnaik, Terra L Lasho, Christy M Finke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasmsAnimesh Pardanani, Terra L Lasho, Christy M Finke, et al.
Pageof 7